The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review

Abstract

Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders of the gastrointestinal tract including Crohn's disease and ulcerative colitis, which may result in several extraintestinal complications (∼20–30% of cases), such as increased risk of venous thromboembolism (VTE). The main pathophysiological mechanism of VTE is an inflammation-induced hypercoagulable state, and recent data have shown that endothelial dysregulation due to gut and systemic inflammation may also lead to a prothrombotic state. Several prothrombotic alterations have been described, such as the activation of the coagulation system, platelet abnormalities, and dysregulation of fibrinolysis. Furthermore, the dysregulation of the gut microbiome seems to play a vital role in increasing systemic inflammation and thus inducing a procoagulant state. Our review aims to examine the main correlations between IBD and VTE, the underlying pathophysiology, and current therapeutic options.

Keywords

immunothrombosis - hypercoagulability - pulmonary embolism - thromboinflammation - venous thrombosis

Publication History

Article published online:
01 December 2022

• References

• 1 Vegh Z, Kurti Z, Gonczi L. et al. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scand J Gastroenterol 2016; 51 (07) 848-854
• 2 Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011; 106 (04) 741-747
• 3 Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol 2014; 20 (38) 13863-13878
• 4 Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85 (03) 430-434
• 5 Bafford AC, Cross RK. Risk of venous thromboembolism in patients with inflammatory bowel disease extends beyond hospitalization. Inflamm Bowel Dis 2020; 26 (11) 1769-1770
• 6 Setyawan J, Mu F, Zichlin ML. et al. Risk of thromboembolic events and associated healthcare costs in patients with inflammatory bowel disease. Adv Ther 2022; 39 (01) 738-753
• 7 Papay P, Miehsler W, Tilg H. et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohn's Colitis 2013; 7 (09) 723-729
• 8 Faye AS, Lee KE, Dodson J. et al. Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis. Aliment Pharmacol Ther 2022; 56 (07) 1157-1167
• 9 Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99 (01) 97-101
• 10 Landman C, Nahon S, Cosnes J. et al; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19 (03) 582-589
• 11 DeFilippis EM, Barfield E, Leifer D. et al. Cerebral venous thrombosis in inflammatory bowel disease. J Dig Dis 2015; 16 (02) 104-108
• 12 Nylund CM, Goudie A, Garza JM, Crouch G, Denson LA. Venous thrombotic events in hospitalized children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56 (05) 485-491
• 13 Quera R, Shanahan F. Thromboembolism – an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004; 99 (10) 1971-1973
• 14 Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W. et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139 (03) 779-787 , 87.e1
• 15 Bollen L, Vande Casteele N, Peeters M. et al. The occurrence of thrombosis in inflammatory bowel disease is reflected in the clot lysis profile. Inflamm Bowel Dis 2015; 21 (11) 2540-2548
• 16 Galanaud JP, Holcroft CA, Rodger MA. et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J Thromb Haemost 2013; 11 (03) 474-480
• 17 Cromer WE, Mathis JM, Granger DN, Chaitanya GV, Alexander JS. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 2011; 17 (05) 578-593
• 18 Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24 (08) 1374-1383
• 19 Palkovits J, Novacek G, Kollars M. et al. Tissue factor exposing microparticles in inflammatory bowel disease. J Crohn's Colitis 2013; 7 (03) 222-229
• 20 Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992; 102 (Pt 4): 821-832
• 21 Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269 (42) 26486-26491
• 22 Stouthard JM, Levi M, Hack CE. et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76 (05) 738-742
• 23 Jones SC, Banks RE, Haidar A. et al. Adhesion molecules in inflammatory bowel disease. Gut 1995; 36 (05) 724-730
• 24 Vetrano S, Ploplis VA, Sala E. et al. Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proc Natl Acad Sci U S A 2011; 108 (49) 19830-19835
• 25 Remková A, Kovácová E, Príkazská M, Kratochvíl'ová H. Thrombomodulin as a marker of endothelium damage in some clinical conditions. Eur J Intern Med 2000; 11 (02) 79-84
• 26 Scaldaferri F, Sans M, Vetrano S. et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 2007; 117 (07) 1951-1960
• 27 Souto JC, Martínez E, Roca M. et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40 (09) 1883-1889
• 28 Reichman-Warmusz E, Kurek J, Gabriel A. et al. Tissue hemostasis and chronic inflammation in colon biopsies of patients with inflammatory bowel disease. Pathol Res Pract 2012; 208 (09) 553-556
• 29 Cibor D, Owczarek D, Butenas S, Salapa K, Mach T, Undas A. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. World J Gastroenterol 2017; 23 (26) 4796-4805
• 30 Meucci G, Pareti F, Vecchi M, Saibeni S, Bressi C, de Franchis R. Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol 1999; 34 (03) 287-290
• 31 Stevens TR, James JP, Simmonds NJ. et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33 (04) 502-506
• 32 Andrade AR, da Rocha TRF, Ortiz-Agostinho CL. et al. Endoscopic activity, tissue factor and Crohn's disease: findings in clinical remission patients. Therap Adv Gastroenterol 2020; 13: 1756284820939412
• 33 Tripodi A, Spina L, Pisani LF. et al. Anti-TNF-α treatment reduces the baseline procoagulant imbalance of patients with inflammatory bowel diseases. Inflamm Bowel Dis 2021; 27 (12) 1901-1908
• 34 Boehme MW, Autschbach F, Zuna I. et al. Elevated serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis. Gastroenterology 1997; 113 (01) 107-117
• 35 Alkim H, Ayaz S, Alkim C, Ulker A, Sahin B. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin Appl Thromb Hemost 2011; 17 (06) 600-604
• 36 Hayat M, Ariëns RA, Moayyedi P, Grant PJ, O'Mahony S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14 (03) 249-256
• 37 Saibeni S, Saladino V, Chantarangkul V. et al. Increased thrombin generation in inflammatory bowel diseases. Thromb Res 2010; 125 (03) 278-282
• 38 de Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989; 30 (02) 188-194
• 39 Yazici A, Senturk O, Aygun C, Celebi A, Caglayan C, Hulagu S. Thrombophilic risk factors in patients with inflammatory bowel disease. Gastroenterol Res 2010; 3 (03) 112-119
• 40 Steinhoff M, Buddenkotte J, Shpacovitch V. et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005; 26 (01) 1-43
• 41 Dolapcioglu C, Soylu A, Kendir T. et al. Coagulation parameters in inflammatory bowel disease. Int J Clin Exp Med 2014; 7 (05) 1442-1448
• 42 Kjeldsen J, Lassen JF, Brandslund I, Schaffalitzky de Muckadell OB. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998; 33 (06) 637-643
• 43 Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World J Gastroenterol 2005; 11 (48) 7639-7645
• 44 Chamouard P, Grunebaum L, Wiesel ML. et al. Significance of diminished factor XIII in Crohn's disease. Am J Gastroenterol 1998; 93 (04) 610-614
• 45 Saibeni S, Bottasso B, Spina L. et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99 (10) 1966-1970
• 46 Owczarek D, Undas A, Foley JH, Nesheim ME, Jabłonski K, Mach T. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. J Crohn's Colitis 2012; 6 (01) 13-20
• 47 Schmid W, Vogelsang H, Papay P. et al. Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease. J Crohn's Colitis 2014; 8 (06) 495-503
• 48 Ye L, Zhang YP, Yu N, Jia YX, Wan SJ, Wang FY. Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: a pilot study. Medicine (Baltimore) 2017; 96 (11) e6323
• 49 Gardiner KR, Halliday MI, Barclay GR. et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36 (06) 897-901
• 50 Panés J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998; 114 (05) 1066-1090
• 51 Hsieh HJ, Liu CA, Huang B, Tseng AH, Wang DL. Shear-induced endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications. J Biomed Sci 2014; 21 (01) 3
• 52 Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy 2020; 16 (01) 38-51
• 53 Kappelman MD, Horvath-Puho E, Sandler RS. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60 (07) 937-943
• 54 Danese S, Katz JA, Saibeni S. et al. Gut 2003; 52 (10) 1435-1441
• 55 Ando K, Fujiya M, Nomura Y. et al. The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease: a retrospective cohort study. Intest Res 2018; 16 (03) 416-425
• 56 Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106 (04) 840-845
• 57 Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol 2005; 83 (02) 196-198
• 58 Faure E, Equils O, Sieling PA. et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 2000; 275 (15) 11058-11063
• 59 Hasan RA, Koh AY, Zia A. The gut microbiome and thromboembolism. Thromb Res 2020; 189: 77-87
• 60 Pastorelli L, Dozio E, Pisani LF. et al. Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function. Gastroenterol Res Pract 2015; 2015: 189341
• 61 Santilli F, Boccatonda A, Davì G. Coagulation at the crossroads of the communicable/non-communicable disease dyad: the case of pneumonia. Respirology 2016; 21 (08) 1344-1346
• 62 Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Semin Thromb Hemost 2012; 38 (05) 506-514
• 63 Faye AS, Wen T, Ananthakrishnan AN. et al. Acute venous thromboembolism risk highest within 60 days after discharge from the hospital in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020; 18 (05) 1133-1141 .e3
• 64 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375 (9715): 657-663
• 65 Weng MT, Park SH, Matsuoka K. et al. Incidence and risk factor analysis of thromboembolic events in East Asian patients with inflammatory bowel disease, a multinational collaborative study. Inflamm Bowel Dis 2018; 24 (08) 1791-1800
• 66 Alhassan N, Trepanier M, Sabapathy C. et al. Risk factors for post-discharge venous thromboembolism in patients undergoing colorectal resection: a NSQIP analysis. Tech Coloproctol 2018; 22 (12) 955-964
• 67 McKechnie T, Wang J, Springer JE, Gross PL, Forbes S, Eskicioglu C. Extended thromboprophylaxis following colorectal surgery in patients with inflammatory bowel disease: a comprehensive systematic clinical review. Colorectal Dis 2020; 22 (06) 663-678
• 68 Kim TJ, Kong SM, Shin JB. et al. P196 risk of venous thromboembolism according to disease activity, hospitalisation, or surgery in inflammatory bowel disease: a nationwide cohort study. Journal of Crohn's and Colitis 2019; 13 (Suppl 1): S189-S190
• 69 Benlice C, Holubar SD, Gorgun E. et al. Extended venous thromboembolism prophylaxis after elective surgery for IBD patients: nomogram-based risk assessment and prediction from nationwide cohort. Dis Colon Rectum 2018; 61 (10) 1170-1179
• 70 Bhandari S, Mohammed Abdul MK, Dhakal B, Kreuziger LB, Saeian K, Stein D. Increased rate of venous thromboembolism in hospitalized inflammatory bowel disease patients with Clostridium difficile infection. Inflamm Bowel Dis 2017; 23 (10) 1847-1852
• 71 Anderson A, Click B, Ramos-Rivers C. et al. Lasting impact of Clostridium difficile infection in inflammatory bowel disease: a propensity score matched analysis. Inflamm Bowel Dis 2017; 23 (12) 2180-2188
• 72 Ananthakrishnan AN, Cagan A, Gainer VS. et al. Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12 (11) 1905-1910
• 73 Simion C, Campello E, Bensi E. et al. Use of glucocorticoids and risk of venous thromboembolism: a narrative review. Semin Thromb Hemost 2021; 47 (06) 654-661
• 74 Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system?. Postgrad Med J 1994; 70 (830) 863-870
• 75 Sandborn WJ, Lawendy N, Danese S. et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2022; 55 (04) 464-478
• 76 Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol 2021; 40 (11) 4457-4471
• 77 FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR): FDA drug safety communication. 2019
• 78 Deepak P, Alayo QA, Khatiwada A. et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2021; 19 (08) 1592-1601 .e3
• 79 Koutroubakis IE, Sfiridaki A, Tsiolakidou G. et al. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis 2007; 13 (04) 410-415
• 80 Guédon C, Le Cam-Duchez V, Lalaude O, Ménard JF, Lerebours E, Borg JY. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96 (05) 1448-1454
• 81 Papa A, De Stefano V, Gasbarrini A. et al. Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 2000; 11 (05) 499-503
• 82 Cattaneo M, Vecchi M, Zighetti ML. et al. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications?. Thromb Haemost 1998; 80 (04) 542-545
• 83 Danese S, Sgambato A, Papa A. et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol 2005; 100 (04) 886-895
• 84 Koutroubakis IE, Petinaki E, Anagnostopoulou E. et al. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1998; 43 (11) 2507-2512
• 85 Sipeki N, Davida L, Palyu E. et al. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease. World J Gastroenterol 2015; 21 (22) 6952-6964
• 86 Koutroubakis IE, Malliaraki N, Vardas E. et al. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?. Eur J Gastroenterol Hepatol 2001; 13 (12) 1415-1419
• 87 Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103 (09) 2272-2280
• 88 Miehsler W, Reinisch W, Valic E. et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004; 53 (04) 542-548
• 89 van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14 (04) 413-418
• 90 Hansen AT, Erichsen R, Horváth-Puhó E, Sørensen HT. Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period. J Thromb Haemost 2017; 15 (04) 702-708
• 91 Kim YH, Pfaller B, Marson A, Yim HW, Huang V, Ito S. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (38) e17309
• 92 Vrij AA, Rijken J, van Wersch JW, Stockbrügger RW. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 2003; 33 (02) 75-83
• 93 Nguyen GC, Bernstein CN, Bitton A. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146 (03) 835-848 .e6
• 94 Mowat C, Cole A, Windsor A. et al; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60 (05) 571-607
• 95 Harbord M, Annese V, Vavricka SR. et al; European Crohn's and Colitis Organisation. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn's Colitis 2016; 10 (03) 239-254
• 96 Scoville EA, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis 2014; 20 (04) 631-636
• 97 Nguyen GC, Murthy SK, Bressler B. et al; CINERGI Group. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: a multicenter retrospective study. Inflamm Bowel Dis 2017; 23 (05) 695-701
• 98 Ra G, Thanabalan R, Ratneswaran S, Nguyen GC. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohn's Colitis 2013; 7 (10) e479-e485
• 99 Faye AS, Hung KW, Cheng K. et al. Minor hematochezia decreases use of venous thromboembolism prophylaxis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2020; 26 (09) 1394-1400
• 100 Lee KE, Lim F, Colombel JF, Hur C, Faye AS. Cost-effectiveness of venous thromboembolism prophylaxis after hospitalization in patients with inflammatory bowel disease. Inflamm Bowel Dis 2022; 28 (08) 1169-1176
• 101 Cotton CC, Baird D, Sandler RS, Long MD. Hormonal contraception use is common among patients with inflammatory bowel diseases and an elevated risk of deep vein thrombosis. Inflamm Bowel Dis 2016; 22 (07) 1631-1638
• 102 Pellino G, Sciaudone G, Caprio F. et al. Hormonal contraceptives and venous thromboembolism: are inflammatory bowel disease patients at increased risk? A retrospective study on a prospective database. Ann Med Surg (Lond) 2015; 4 (04) 462-466
• 103 Curtis KM, Tepper NK, Jatlaoui TC. et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65 (03) 1-103
• 104 Lobo JL, Garcia-Fuertes JA, Trujillo-Santos J. et al; RIETE Investigators. Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2018; 30 (05) 526-530
• 105 Comerota AJ. Pharmacologic and pharmacomechanical thrombolysis for acute deep vein thrombosis: focus on ATTRACT^CME . Methodist DeBakey Cardiovasc J 2018; 14 (03) 219-227
• 106 Campello E, Spiezia L, Simion C. et al. Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Assoc 2020; 9 (23) e018917
• 107 Viola A, Chiappetta MF, Scolaro M, Bignoli F, Versace A, Fries W. Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease. Dig Liver Dis 2020; 52 (12) 1525-1526
• 108 Cai TQ, Wu W, Shin MK. et al. Factor XII full and partial null in rat confers robust antithrombotic efficacy with no bleeding. Blood Coagul Fibrinolysis 2015; 26 (08) 893-902
• 109 Larsson M, Rayzman V, Nolte MW. et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6 (222) 222ra17
• 110 Nourse J, Danckwardt S. A novel rationale for targeting FXI: insights from the hemostatic microRNA targetome for emerging anticoagulant strategies. Pharmacol Ther 2021; 218: 107676
• 111 Al-Horani RA. Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present). Expert Opin Ther Pat 2020; 30 (01) 39-55
• 112 DeLoughery EP, Olson SR, Puy C, McCarty OJT, Shatzel JJ. The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials. Semin Thromb Hemost 2019; 45 (05) 502-508